$BETRF News

BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director

BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco

BetterLife Pharma Provides Scientific Update on Neuroplastogenic Activity of BETR-001

BetterLife Provides Comments on CEO’s Share Position Ownership and Recent BCSC Press Release

BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders

BetterLife Announces Debt Settlements

BetterLife Pharma Appoints Corporate Advisor

BetterLife Pharma Appoints New Director

BetterLife Announces Debt Conversions

USPTO Grants BetterLife’s BETR-001 Composition of Matter Patent

BetterLife Announces Favorable Outcome in New York Legal Claims

BetterLife Obtains Favourable Cardiac Safety Data for BETR-001

BetterLife Obtains Favourable Genotoxicity Data for Oral BETR-001

BetterLife Announces Fully Subscribed Private Placement Financing

BetterLife Highlights Advantages of Non-hallucinogenic LSD Derivative BETR-001 and Publication of its Methods to Treat Mood Disorders Patent

Amendment of Disclosures in Past Management Information Circulars

BetterLife Announces Closing of a Private Placement

BetterLife To Present BETR-001 Preclinical Data at the 2024 Conference of the Federation of European Neuroscience Societies (FENS) in Vienna, Austria